X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6731) 6731
male (6324) 6324
prostate cancer (5113) 5113
prostatic neoplasms - pathology (3742) 3742
oncology (3125) 3125
cancer (2403) 2403
metastasis (2124) 2124
cell line, tumor (2055) 2055
aged (2021) 2021
animals (1940) 1940
middle aged (1853) 1853
prostatic neoplasms - metabolism (1689) 1689
prostatic neoplasms, castration-resistant - pathology (1612) 1612
prostatic neoplasms - genetics (1527) 1527
prostate (1454) 1454
urology & nephrology (1403) 1403
prostatic neoplasms - drug therapy (1308) 1308
expression (1288) 1288
mice (1247) 1247
research (1228) 1228
care and treatment (1192) 1192
tumors (1180) 1180
prognosis (1058) 1058
androgens (1033) 1033
analysis (1018) 1018
androgen receptor (1014) 1014
prostatic neoplasms, castration-resistant - drug therapy (1006) 1006
chemotherapy (999) 999
survival (965) 965
development and progression (954) 954
aged, 80 and over (939) 939
gene expression (932) 932
gene expression regulation, neoplastic (914) 914
neoplasm metastasis (912) 912
disease progression (911) 911
treatment outcome (903) 903
progression (892) 892
receptors, androgen - metabolism (849) 849
metastases (847) 847
cell biology (801) 801
castration (782) 782
apoptosis (776) 776
bone neoplasms - secondary (761) 761
docetaxel (757) 757
health aspects (748) 748
urology (736) 736
cancer therapies (728) 728
genetic aspects (696) 696
cell proliferation (666) 666
antineoplastic agents - therapeutic use (659) 659
proteins (659) 659
therapy (653) 653
signal transduction (636) 636
prostatic neoplasms - therapy (606) 606
prostate-specific antigen - blood (605) 605
cells (598) 598
medicine (598) 598
growth (597) 597
research article (596) 596
patients (592) 592
prostate-cancer (582) 582
endocrinology & metabolism (571) 571
receptors, androgen - genetics (565) 565
neoplasm staging (557) 557
immunohistochemistry (550) 550
men (536) 536
female (535) 535
breast-cancer (527) 527
radical prostatectomy (527) 527
carcinoma (525) 525
biomarkers (521) 521
biochemistry & molecular biology (519) 519
prostatic neoplasms, castration-resistant - metabolism (514) 514
multidisciplinary sciences (509) 509
retrospective studies (504) 504
medicine & public health (496) 496
cell proliferation - drug effects (492) 492
prostate - pathology (488) 488
urologic and male genital diseases (485) 485
mice, nude (482) 482
adult (480) 480
risk factors (480) 480
prostatic neoplasms, castration-resistant - genetics (479) 479
prostatic neoplasms - mortality (474) 474
androgen antagonists - therapeutic use (472) 472
disease-free survival (468) 468
medical research (468) 468
antineoplastic agents - pharmacology (467) 467
prostatic neoplasms - surgery (464) 464
neoplasm grading (460) 460
xenograft model antitumor assays (455) 455
kinases (442) 442
oncology, experimental (422) 422
medical prognosis (421) 421
pathology (420) 420
studies (415) 415
diagnosis (414) 414
castration-resistant prostate cancer (408) 408
orchiectomy (408) 408
cancer research (405) 405
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7238) 7238
German (38) 38
Japanese (28) 28
French (23) 23
Chinese (12) 12
Spanish (12) 12
Hungarian (4) 4
Danish (2) 2
Italian (2) 2
Russian (2) 2
Czech (1) 1
Dutch (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature medicine, ISSN 1546-170X, 2016, Volume 22, Issue 3, pp. 298 - 305
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 65, Issue 2, pp. 270 - 273
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 65, Issue 2, pp. 467 - 479
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 26, pp. 2465 - 2474
Journal Article
Nature (London), ISSN 1476-4687, 2017, Volume 543, Issue 7647, pp. 728 - 732
A significant fraction of patients with advanced prostate cancer treated with androgen deprivation therapy experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC)(1... 
BREAST-CANCER | IMMUNE-SYSTEM | THERAPY | MULTIDISCIPLINARY SCIENCES | MOUSE | DOUBLE-BLIND | PHASE-3 TRIAL | TYROSINE KINASE INHIBITOR | SUPPRESSOR-CELLS | MYELOID CELLS | CHECKPOINT BLOCKADE | Anilides - therapeutic use | Immunotherapy - methods | Humans | Prostatic Neoplasms, Castration-Resistant - immunology | Male | Myeloid-Derived Suppressor Cells - drug effects | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - pathology | Quinolines - pharmacology | Myeloid-Derived Suppressor Cells - cytology | Prostatic Neoplasms, Castration-Resistant - therapy | Female | Imidazoles - therapeutic use | Cytokines - immunology | Disease Models, Animal | Pyridines - therapeutic use | Tumor Microenvironment - drug effects | Myeloid-Derived Suppressor Cells - immunology | Cytokines - metabolism | Imidazoles - pharmacology | Lymphocytes, Tumor-Infiltrating - drug effects | Drug Synergism | Tumor Microenvironment - immunology | Animals | Signal Transduction - drug effects | CD8-Positive T-Lymphocytes - drug effects | Anilides - pharmacology | Mice | Pyridines - pharmacology | Quinolines - therapeutic use | CD8-Positive T-Lymphocytes - immunology | Chimera | Lymphocytes, Tumor-Infiltrating - immunology | Care and treatment | Metastasis | Prostate cancer | Analysis | Immunotherapy | Patient outcomes | Cancer therapies | Tumors
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 152 - 160
Journal Article
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 66, Issue 5, pp. 815 - 825
Abstract Background Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC... 
Urology | Chemotherapy-naive | Efficacy | Safety | Metastatic castration-resistant prostate cancer | Abiraterone acetate | prostate cancer | Metastatic castration-resistant | PLACEBO | DOCETAXEL CHEMOTHERAPY | PHASE-3 | TRIAL | MITOXANTRONE PLUS PREDNISONE | THERAPY | MEN | UROLOGY & NEPHROLOGY | INCREASED SURVIVAL | LIFE | Neoplasms, Hormone-Dependent - mortality | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - enzymology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytochrome P-450 Enzyme Inhibitors - adverse effects | Male | Abiraterone Acetate | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Time Factors | Neoplasms, Hormone-Dependent - enzymology | Prednisone - administration & dosage | Androstenes - adverse effects | Double-Blind Method | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Androstenes - administration & dosage | Cytochrome P-450 Enzyme Inhibitors - administration & dosage | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Hormone-Dependent - pathology | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Steroid 17-alpha-Hydroxylase - metabolism | Neoplasms, Hormone-Dependent - drug therapy | Medical colleges | Cancer patients | Care and treatment | Chemotherapy | Corticosteroids | Analysis | Metastasis | Prostate cancer | Acetates | Cancer
Journal Article